KYNTRA BIO CEO Wettig Thane forfeited 209 shares at $8.55 per share. The transaction left him with 26,796 shares and represented about 0.8% of his prior holding, giving investors the disclosed scale of the Withholding against his ownership position.
Key Highlights
- The transaction occurred on Sep. 6, 2026, under code F.
- Wettig Thane’s reported ownership stood at 26,796 shares after the transaction.
- The forfeiture represented about 0.8% of his prior shareholding.
KYNTRA BIO, INC. (NASDAQ: KYNB) CEO Wettig Thane forfeited 209 shares at $8.55 per share. Following the transaction, his reported ownership stood at 26,796 shares.
KYNTRA BIO Executive Ownership Details
The transaction occurred on Sep. 6, 2026, and carried transaction code F. The action covered 209 shares, and the filing reports $8.55 per share. Wettig Thane is identified as KYNTRA BIO’s CEO. The reported figures separate the transaction quantity, the per-share amount and the resulting ownership balance. The 209 shares refer to the forfeiture itself, while the $8.55 amount applies to each forfeited share. The 26,796-share figure applies after the transaction, rather than to the number of shares involved in it.
Forfeiture Measured Against Prior Holding
The reported 0.8% figure is measured against Wettig Thane’s prior shareholding. The disclosed ownership after the transaction was 26,796 shares, and the stated price was $8.55 per share. Transaction code F denotes shares withheld or delivered to cover taxes or an exercise price.
FAQs
Q: What happened to Wettig Thane’s KYNTRA BIO shares?
A: KYNTRA BIO CEO Wettig Thane forfeited 209 shares at $8.55 per share on Sep. 6, 2026. The transaction carried code F, and his reported ownership afterward stood at 26,796 shares.
Q: How many KYNTRA BIO shares does Wettig Thane own after the transaction?
A: Following the reported forfeiture, Wettig Thane owned 26,796 KYNTRA BIO shares. The filing states this was his ownership balance after 209 shares were forfeited at $8.55 per share.
Q: What percentage of Wettig Thane’s holding did the transaction represent?
A: The KYNTRA BIO share forfeiture represented about 0.8% of Wettig Thane’s prior shareholding. That percentage measures the transaction against his own earlier position.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.